KOL Perspectives: BTK Inhibitors in RA

Summary

This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.

Questions topics -

• Awareness and potential of BTK inhibitors in RA


• Perceptions of BMS-986142’s Phase IItrial design


• Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA

Key Highlights

• Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS-986142, despite its lack of Phase II data


• KOLs were divided over BMS-986142’s ability to achieve ACR70 by Week 12 in a refractory patient population


• For the majority of KOLs, poseltinib’s discontinuation had little to no impact on their existing perception of BTK inhibitors in RA.

Scope

• The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -

• 5 Europe-based & 5 N. America-based


• Interviews performed during Q2 2018

KOL data is analyzed to produce -

• Charts summarizing KOL opinions


• Chart call-outs of key information & details


• KOL quotes


• Summary of KOL reporting trends


• Insight from Sociable Pharma's analysts

Reasons to Buy

• Combines Qualitative & semi-quantitative insight from key opinion leaders on BTK Inhibitors in RA


• Includes insight & recommendations from our disease-specific healthcare analysts


• Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA


• Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.